We scan new podcasts and send you the top 5 insights daily.
Warma says ProMIS chose a 140-patient, 12-month phase 1b instead of a quick 30-patient biomarker study. By checking safety, target engagement, dose, and clinical signal, they hope to move straight into a registration phase 3, saving years and cost. He says the longer, costlier design was deliberate because short biomarker studies left partners unsure.
Warma lists the prerequisites for a registration study: deliver the drug safely, cross the blood-brain barrier to engage target, show biomarker movement, identify a dose, and demonstrate clinical benefit. ProMIS has fast-track designation and plans an end-of-phase-2 FDA meeting. He says these are the boxes that must be checked before starting phase 3.
Instead of stopping a trial early for success—which regulators may restrict—a high-confidence early signal provides immense value as business intelligence. This allows sponsors to de-risk and accelerate planning for subsequent phases months earlier, creating millions in value by reducing the gap between Phase 2 and 3.
Leveraging strong existing academic data on its drug's core component, Alto Neuro is taking a calculated risk. By using recent financing to launch a Phase 3 study before its Phase 2b trial concludes, the company aims to compress its development timeline and submit its approval package to the FDA much sooner than a sequential approach would allow.
To combat high failure rates in CNS, Autobahn designed its Phase 2 study with the statistical power of a Phase 3 trial (+90%). This capital-intensive approach aims to get a definitive answer on drug efficacy early, increasing confidence for a successful Phase 3 replication and avoiding larger, later-stage flameouts.
Instead of running separate Phase 2 and 3 trials, iOnctura plans to "operationally upsize" its current study. This involves keeping the same clinical sites open and transitioning directly into a Phase 3 cohort with new patients, creating a more efficient, faster, and less costly path to potential approval.
The AI-driven antibody engineering firm is moving its lead TSLP compound directly from Phase 1 into two Phase 3 trials. This aggressive timeline demonstrates platform confidence but introduces significant clinical risk by skipping a key data-gathering stage.
The extensive translational and biomarker work published in Nature from a Phase 1 study of Casdatifan is a model for modern drug development. Understanding the drug's mechanism, pharmacodynamics, and response signatures from day one provides a 'backup plan' and helps avoid costly Phase 3 failures.
Warma says when ProMIS proposed the larger phase 1b, investors were more interested than in a quick-and-dirty study because they saw the path to skipping phase 2. Pharma partners also responded well to the comprehensive design. He notes the tradeoff is a longer public-company news wait and higher cost, but the pros outweighed cons.
Based on strong Phase 1b data, Celcuity's leadership decided the probability of success was high enough to skip a randomized Phase 2 trial. They concluded that delaying development by three years would be more detrimental than the financial risk of going directly to Phase 3.
Unlike big pharma, capital-constrained biotechs can't afford long, expensive trials. MindImmune’s CEO advocates for designing clever Phase 1b studies that use biomarker endpoints to get an early efficacy signal in months, not years, thereby de-risking the program for investors much faster.